Diagonal Therapeutics
Last verified 2026-06-13. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $253.0Mattributed |
|---|---|
| Latest round | series-b, $125.0M, 2026-01-08attributed |
| Founded | 2022 |
| Headquarters | Cambridge |
| Industry | healthtech |
| Stage | series-b+ |
| Website | diagonaltx.com |
Diagonal Therapeutics develops clustering antibodies that bind multiple receptors at once to regulate signaling and modify disease at its root. It targets genetic and chronic conditions like hereditary hemorrhagic telangiectasia and pulmonary hypertension. Its edge is an engine screening billions of antibody combinations to design them.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-01-08 | series-b | $125.0M | undisclosed |
Detected tech stack
adobe fonts, hsts, netlify, next.js, react, typekit, webpack
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $125.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $253.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | diagonaltx.com, read 2026-06-13 |
| Description | self-reported | diagonaltx.com, read 2026-06-13 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.